Reasons To Own AbbVie After Abbott Splits In Two Seeking Alpha Abbott also expects Phase III results for Daclizumab in 2014. The drug is used to treat multiple sclerosis, an inflammatory disease affecting the nervous system affecting an estimated 2.1 million worldwide. Currently, the disease is treated with ... |
